These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23657379)

  • 21. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
    Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
    [No Abstract]   [Full Text] [Related]  

  • 22. Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis.
    Baldelli S; Fusi M; Cozzi V; Clementi E; Faelli NML; Russo M; Colombo C; Cattaneo D
    Clin Chem Lab Med; 2019 Oct; 57(11):e274-e278. PubMed ID: 31141479
    [No Abstract]   [Full Text] [Related]  

  • 23. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

  • 24. Vertex CF data wow Wall Street.
    Nat Biotechnol; 2017 Sep; 35(9):807. PubMed ID: 28898228
    [No Abstract]   [Full Text] [Related]  

  • 25. 2015 American Thoracic Society International Conference.
    Akkermans R
    Lancet Respir Med; 2015 Jul; 3(7):513-5. PubMed ID: 26025260
    [No Abstract]   [Full Text] [Related]  

  • 26. Update in Cystic Fibrosis 2014.
    Ong T; Ramsey BW
    Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
    [No Abstract]   [Full Text] [Related]  

  • 27. Game Changers.
    Ulster Med J; 2015 Oct; 84(3):218-9. PubMed ID: 26668427
    [No Abstract]   [Full Text] [Related]  

  • 28. Breathing easier with combinations.
    Azvolinsky A
    Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
    [No Abstract]   [Full Text] [Related]  

  • 29. Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States.
    Sawicki GS; Fink AK; Schechter MS; Loeffler DR; Mayer-Hamblett N
    J Cyst Fibros; 2018 Nov; 17(6):742-746. PubMed ID: 30201329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4
    Roehmel JF; Ogese MO; Rohrbach A; Mall MA; Naisbitt DJ
    J Allergy Clin Immunol; 2021 Feb; 147(2):753-756. PubMed ID: 32526307
    [No Abstract]   [Full Text] [Related]  

  • 31. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
    McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
    Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
    Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Organoid Swelling and
    Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398
    [No Abstract]   [Full Text] [Related]  

  • 37. Remarkable progress toward new treatments for cystic fibrosis.
    Eldredge LC; Ramsey BW
    Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
    [No Abstract]   [Full Text] [Related]  

  • 38. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.